Zirconium-89 (89Zr)labeled atezolizumab (anti-PD-L1 antibody) was used to visualize the dynamic presence of PD-L1 in mice bearing orthotopic glioblastoma tumors and in patients with newly diagnosed glioblastoma.21 Immuno-PET specifically detected tumor and immune cell PD-L1, even after neoadjuvant Pembrolizumab. This evidence concerns the gene CD274 and neoplasm.